Melanotan-1
FDA ApprovedAn FDA-approved synthetic analog of alpha-MSH that selectively activates MC1R to stimulate eumelanin production. Approved as Scenesse for erythropoietic protoporphyria (EPP), making it the first and only treatment for this rare photosensitivity disorder.
Afamelanotide · Scenesse · NDP-MSH · [Nle4,D-Phe7]-α-MSH · MT-I · MT-1 · CUV1647
6 human studies
- Preclinical
- 44%
- Clinical
- 33%
Based on 18 cited sources
clinically demonstrated · moderate confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 74: two pivotal placebo-controlled RCTs (Langendonk NEJM 2015 26132941, US N=93 + EU N=74) at low risk of bias (1A 30, 1B 17), supplemented by observational cohorts (Biolcati 115 patients 25494545; German cohort 40082741) bringing total human N ~300+ (1C 8); evidence direct on EPP population/implant route/pain-free-hours outcome (1D 13); substantial but not extensively replicated preclinical melanocyte/MC1R program (1E 6). Mechanism 79: MC1R named target with alpha-MSH-analog binding + functional cAMP response and MC1R-dependent effects (2A 30), full cAMP/PKA/MITF/tyrosinase->eumelanin pathway characterized (2B 27), dose-response in models and in vivo (2C 13), confirmed in mammalian/human in vivo (2D 9). Plausibility 85: full mechanism->surrogate(eumelanin/UV absorption)->clinical(pain-free hours, reduced phototoxic reactions) chain each independently RCT-supported (3A 33), fully coherent with melanocortin photoprotection physiology (3B 24), class analogy from other melanocortin agonists (3C 15), tightly scoped EPP claim (3D 13). Global Coverage 68: replicated across US, Netherlands, Italy, Switzerland, Germany, Austria (4A 22, 4B 18) with a moderate orphan-disease literature (~18 sources, 4C 13) and dual FDA+EMA approval (4D 15). Community Experience 60: niche but persistent EPP-patient and enthusiast use (5A 12), >7-year track record since 2014 EMA approval (5B 23), broadly consistent QoL reports (5C 13), no recurring serious adverse signal over substantial exposure (5D 12) — real-world usage signal only, NOT evidence of efficacy or safety. Effectiveness basis clinical (moderate): pivotal RCTs showed 69.4 vs 40.8 median pain-free hours and reduced phototoxic reactions, with real-world cohorts reporting large QoL gains (Austrian PBTT 15->250 min, QoL 11->79); moderate-large effect on hard patient-relevant outcomes, first-in-class with no active comparator, confidence capped moderate by small orphan-disease trial sizes.
Melanotan-1 (afamelanotide) is a synthetic 13-amino acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that selectively activates MC1R receptors on melanocytes to stimulate eumelanin production, making it the first FDA-approved treatment for erythropoietic protoporphyria (EPP).
How It Works (Simplified)
Melanotan-1 acts as a targeted MC1R agonist, producing photoprotection through a defined melanocortin signaling cascade:
Afamelanotide binds to MC1R receptors on melanocytes with high selectivity, unlike non-selective Melanotan-II which also activates MC3R, MC4R, and MC5R. This selectivity eliminates the CNS and cardiovascular effects associated with multi-receptor melanocortin agonism.
MC1R activation triggers the intracellular cAMP/PKA/MITF cascade, upregulating tyrosinase and related enzymes (TRP-1, TRP-2). This drives synthesis of eumelanin (dark pigment) rather than pheomelanin, increasing protective pigment density in the epidermis.
Increased epidermal eumelanin absorbs UV radiation before it reaches and excites accumulated protoporphyrin IX (PPIX) in EPP patients. By intercepting the photon energy at the melanin layer, phototoxic PPIX excitation is prevented, dramatically reducing pain episodes.
EPP patients gain significantly more pain-free hours in sunlight — 69.4 vs 40.8 median hours over 6 months in the pivotal US trial. Clinical benefit lasts through 60-day implant cycles, enabling near-normal daily activity for patients previously confined to strict sun avoidance.
Key Research: Langendonk JG et al. (2015, NEJM) demonstrated in two randomized placebo-controlled trials that afamelanotide significantly increased pain-free sunlight hours in EPP patients, forming the basis for FDA approval in 2019. PMID:26132941
Important Limitations
- Only FDA-approved for erythropoietic protoporphyria (EPP) — all other uses are off-label and unsupported by evidence
- Small trial populations typical of rare disease studies (N=93 US trial, N=74 EU trial); total pivotal trial enrollment under 200 patients
- Subcutaneous implant must be administered by a trained healthcare provider — cannot be self-administered
- Only available through the restricted Scenesse REMS program in the US
- Long-term safety data beyond 5 years is limited
- Does NOT have the same receptor profile as Melanotan-II — safety and efficacy data between the two compounds is not interchangeable
- Off-label cosmetic tanning use is not evidence-based and not recommended
Afamelanotide implant releases most of its dose within the first 48 hours following subcutaneous implantation. Initial melanocyte activation begins as drug is absorbed systemically. Mild implant site reactions (bruising, swelling) are common during this period.
PMID:26132941Visible skin darkening begins as eumelanin synthesis ramps up in epidermal melanocytes. Initial photoprotective effect begins emerging. Clinical trial participants reported gradual increase in tolerable sunlight exposure during this period.
PMID:26132941Peak eumelanin levels and maximum photoprotective benefit observed. Pivotal trials showed the greatest increase in pain-free sunlight hours in this window. EPP patients can typically tolerate substantially more outdoor activity compared to pre-treatment baseline.
PMID:26132941Sustained protection with repeat implant at 60-day intervals maintains eumelanin levels. Clinical trial protocol required implants every two months to sustain benefit. Real-world data confirms 91% of patients continue treatment long-term due to sustained benefit.
PMID:40082741Gradual return to baseline skin pigmentation over approximately 1-3 months as existing eumelanin degrades and new melanin synthesis returns to unstimulated baseline. EPP symptoms typically return as photoprotection wanes. No rebound phenomena or withdrawal effects documented.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (4 indicators)
Bad Signs (5 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
PT-141
CompatibleBoth melanocortin analogs but target different receptors and indications. PT-141 (bremelanotide) is MC4R-preferring for HSDD; Melanotan-1 is MC1R-selective for EPP. No overlapping mechanism of concern.
BPC-157
CompatibleNo known interaction. Different targets — BPC-157 for GI/tissue repair, Melanotan-1 for melanocortin-mediated photoprotection.
Melanotan-II
CautionStructurally related alpha-MSH analogs but fundamentally different. Melanotan-II is non-selective (MC1R+MC3R+MC4R+MC5R) and unapproved with significant safety concerns. Do not combine — overlapping melanocortin pathway activation with unpredictable receptor cross-talk.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Melanotan-1
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Cardiogen
AED · Ala-Glu-Asp · Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp, AED) developed by Russian scientist Vladimir Khavinson and marketed as a cardiac "bioregulator." Despite that marketing, no PubMed-indexed study has examined AED in heart, cardiomyocyte, or myocardial tissue. The only published AED research is in vitro and non-cardiac — anti-aging gene-expression effects in cultured stem cells, fibroblasts, kidney and immune cells. No human or animal data and no regulatory approval anywhere.
Chelohart
Heart cytamin · Cardiac peptide supplement · A-7 heart peptides
A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
Chonluten
EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide +1
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.